Novo Nordisk (NVO)
(Delayed Data from NYSE)
$134.88 USD
+2.82 (2.14%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $134.84 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum C VGM
Price, Consensus and EPS Surprise
NVO 134.88 +2.82(2.14%)
Will NVO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NVO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVO
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
NVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Novo Nordisk (NVO) Gains As Market Dips: What You Should Know
Tap the Weight-Loss Drug Market With These ETFs
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Other News for NVO
GLOBAL BRIEFING: Japan leaves interest rates unchanged
2024 ISPE Pharma 4.0? and Annex 1 Conference Featured Speakers Are Announced
Novo Nordisk's Wegovy gets positive EMA opinion for heart treatment
Novo Nordisk: The Street Is Not Seeing The Growth Acceleration Potential
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO